Furthermore, a study by Yue Bi et al. demonstrated that Olaparib is potentially useful as an effective radiosensitizer in BRCA1-deficient high-grade serous ovarian carcinomas using a preclinical model.36 This led us to hypothesize that PARP inhibitors may be used as potential radiosensitizers to enhance the sensitivity of radiotherapy in BRCA2-deficiency YST. Here, PARP1 is linked to ovarian serous carcinoma.